Factor VIII levels at 40%, 3 days after infusion
Hypothetical child and scenario
Factor VIII levels at 40%, 3 days after infusion
Hypothetical child and scenario
A once-weekly Factor VIII replacement therapy with higher-for-longer levels above 40% (near-normal to normal range) for most of the week in adults and for ~3 days in kids.
Sign up today to hear from a CoRe Manager and receive helpful information about ALTUVIIIO
Sign up for the Peer Mentor Program
Connect with a real ALTUVIIIO patient for advice, information about their experience, and more.
Request a Peer Mentor
ALTUVIIIO is a first-in-class, once-weekly treatment for hemophilia A
The unique design of ALTUVIIIO combines 3 components that help Factor VIII levels to stay higher in your body for a longer period of time: vWF Fragments; XTEN Technology; and Fc Fusion.
The unique design of ALTUVIIIO combines 3 components that help Factor VIII levels to stay higher in your body for a longer period of time: vWF Fragments; XTEN Technology; and Fc Fusion.
Factor VIII levels in the near-normal to normal range
ALTUVIIIO is a first-in-class Factor VIII replacement therapy that keeps Factor VIII levels above 40% (near-normal to normal range) for most of the week in adults and for ~3 days in kids–with 1 weekly infusion.*†‡
Factor VIII levels, on average, were:
Factor VIII levels, on average, were:
- 18% in adults 18 years and older
- 9% in adolescents aged 12 years to under 18 years
- 17% in children aged 6 years to under 12 years
- 11% in children aged 1 year to under 6 years
*
Average trough levels were 18% for adults 18 years and older, 9% for adolescents aged 12 years to under 18 years, 17% for children aged 6 years to under 12 years, and 11% for children aged 1 year to under 6 years.
†
159 adults and adolescents with severe hemophilia (aged 12 years and older) were enrolled in the XTEND-1 study; 133 people were in Group 1 and switched to ALTUVIIIO prophylaxis from prior prophylaxis therapy. Efficacy of prophylaxis was evaluated in 128 of these patients.
‡
ALTUVIIIO was studied in the XTEND-Kids study. The primary goal of the study was to determine whether or not children under 12 years of age developed inhibitors to ALTUVIIIO. 0 inhibitors were detected. Efficacy of prophylaxis was evaluated in 72 of these patients.
ALTUVIIIO is designed to help Factor VIII stay in the body longer
In a Phase 3 study,* ALTUVIIIO offered a 48-hour half-life in adults,† the longest half-life of any Factor VIII replacement therapy. ALTUVIIIO uniquely combines 3 components to help it stay in your body longer. All 3 components work together to keep ALTUVIIIO Factor VIII levels higher for longer.
*
159 adults and adolescents with severe hemophilia (aged 12 years and older) were enrolled in the XTEND-1 study; 133 people were in Group 1 and switched to ALTUVIIIO prophylaxis from prior prophylaxis therapy. Efficacy of prophylaxis was evaluated in 128 of these patients.
†
The half-life was 44.6 hours for adolescents aged 12 years to under 18 years, 42.4 hours for children aged 6 years to under 12 years, and 38 hours for children aged 1 year to under 6 years.
ALTUVIIIO provides proven bleed protection
In the XTEND-1 study, participants aged 12 years and older showed proven bleed protection when taking ALTUVIIIO as a prophylaxis treatment.
Data from the XTEND-1 study showed 0.7 mean bleeds per year (primary outcome).
Data from the XTEND-Kids study showed 0.6 mean bleeds per year.*
Data based on treated bleeds.
Once-weekly ALTUVIIIO provides freedom and flexibility
Because ALTUVIIIO has a longer half-life, fewer infusions are needed, providing flexibility and freedom for people with hemophilia A. Infusions are only needed once weekly.
“My advice to people with hemophilia is to constantly be looking for what makes you happy!”
AJ
On ALTUVIIIO prophylaxis since May 2023.
Explore Patient Stories
Copay Savings From ALTUVIIIO*
Eligible patients may pay as little as $0.
*
Terms and restrictions apply.
Discover the Program